Brief: Enanta Pharmaceuticals Doses First Subject In A Phase 1 Clinical Study Of EDP-323, Its Novel, Oral L-Protein Inhibitor In Development For The Treatment Respiratory Syncytial Virus

Enanta Pharmaceuticals

17/10/2022 12:10

Oct 17 (Reuters) - Enanta Pharmaceuticals Inc  ENTA.O :
    * ENANTA PHARMACEUTICALS DOSES FIRST SUBJECT IN A PHASE 1
CLINICAL
STUDY OF EDP-323, ITS NOVEL, ORAL L-PROTEIN INHIBITOR IN
DEVELOPMENT FOR THE TREATMENT RESPIRATORY SYNCYTIAL VIRUS

Source text for Eikon:  ID:nBw8lHZQha 
Further company coverage:  ENTA.O 
 ((Reuters.Briefs@thomsonreuters.com;;))